Connect your AI

Zymeworks ZYME Prepaid & Other Current

Prepaid & Other Current at other companies

AmgenAMGN

$4.11B+26.2%

AnaptysBio, Inc.ANAB

$3.91M-26.2%

Viridian Therapeutics, Inc.VRDN

$22.56M+9.5%

AbCellera Biologics Inc.ABCL

$98.1M+3.6%

Stoke Therapeutics, Inc.STOK

$10.12M-20.3%

Nurix Therapeutics, Inc.NRIX

$13.66M-2.6%

Other financials

Income statement

Revenue$2.4M-91.1%

Operating income-$47.1M-84.0%

Net income-$44.2M-95.1%

EPS (diluted)-$0.59-96.7%

Balance sheet

Cash & equivalents$244.3M+221%

Total debt$17.0M-7.7%

Total equity$163.6M-49.7%

Total assets$478.2M+12.4%

Cash flow

Operating cash flow-$45.7M-1,242%

CapEx$216.0K+1,250%

Free cash flow-$45.9M-1,242%

Valuation

Market cap$1.79B+125%

Profitability

Operating margin-140.4%+7.3pp

Net margin-126.3%+5.0pp

FCF margin-94.8%+15.5pp

Returns & leverage

Return on equity-42%+29.2pp

Debt / equity0.1×0.0×

Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:PrepaidExpenseAndOtherAssetsCurrent.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's prepaid & other current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Zymeworks's prepaid & other current?: Zymeworks (ZYME) reported prepaid & other current of $16.28M in Q1 2026.
How has Zymeworks's prepaid & other current changed year-over-year?: Zymeworks's prepaid & other current decreased by 1.9% year-over-year, from $16.59M to $16.28M.
What is the long-term trend for Zymeworks's prepaid & other current?: Over 2 years (2023 to 2025), Zymeworks's prepaid & other current has grown at a -18.1% compound annual growth rate (CAGR), from $81.17M to $54.47M.
What does prepaid & other current mean?: Advance payments for expenses (rent, insurance, subscriptions) plus miscellaneous current assets not classified elsewhere.